Medicare to help pay for weight-loss GLP-1 drugs in new program

Medicare began helping pay for select GLP-1 weight-loss drugs on July 1, 2026, through a short-term federal demonstration that runs through December 31, 2027. The Medicare GLP-1 Bridge gives eligible Part D beneficiaries access to certain obesity treatments at a $50 monthly copay, while keeping the drugs outside the normal Part D coverage and payment flow.

The Centers for Medicare & Medicaid Services set up the bridge with a central processor that handles prior authorization, claims adjudication and pharmacy payment. The program is meant to expand access to evidence-based weight-loss treatment and gather data on how many people use it, what outcomes follow and how the system works before lawmakers or regulators decide whether to go further.

The launch list is narrow. Medicare’s coverage page lists the drugs available at the start as Foundayo tablets, Wegovy injections or tablets, and Zepbound KwikPen only. Single-dose Zepbound vials or pens are not included.

Eligibility is also limited. KFF estimates about 3.8 million Medicare Part D enrollees could qualify based on 2023 claims data, even though more than 13 million Medicare beneficiaries met BMI thresholds for obesity or overweight that year. In general, beneficiaries must be enrolled in Part D and meet clinical criteria such as a BMI of 35 or more, a BMI of 30 or more with conditions including heart failure with preserved ejection fraction, uncontrolled hypertension or chronic kidney disease stage 3a or above, or a BMI of 27 or more with pre-diabetes, prior heart attack, prior stroke or symptomatic peripheral artery disease.

The bridge also excludes people who already filled a GLP-1 prescription through Part D in 2026 and people whose diagnosis already supports Part D coverage, including type 2 diabetes, obstructive sleep apnea or noncirrhotic metabolic dysfunction-associated steatohepatitis.

CMS delayed the Part D portion of its broader BALANCE Model and extended the bridge to the end of 2027. The American Medical Association has pushed for legislation or regulation requiring insurers to cover GLP-1 drugs for obesity and type 2 diabetes at affordable prices.